Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N,N dimethyltryptamine - Definium Therapeutics

Next Previous
Drug Profile

N,N dimethyltryptamine - Definium Therapeutics

Alternative Names: Dimethyltryptamine - Definium Therapeutics; DMT - Definium Therapeutics; N,N-Dimethyltryptamine - Definium Therapeutics

Latest Information Update: 22 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The University Hospital of Basel
  • Developer Definium Therapeutics; The University Hospital of Basel
  • Class Antidepressants; Antipsychotics; Dimethylamines; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules; Tryptamines; Vascular disorder therapies
  • Mechanism of Action Neuron modulators; Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Mental disorders; Substance-related disorders

Most Recent Events

  • 12 Jan 2026 Mindmed is now called Definium Therapeutics
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Mental-disorders(In volunteers) in Switzerland (IV)
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Mental-disorders in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top